Insmed Inc. (Nasdaq:INSM), (referred to herein as �Insmed�, �we�,
�our� and �us�), a biopharmaceutical company with unique protein
process development and manufacturing experience and a proprietary
protein platform aimed at niche markets with unmet medical needs,
today announced results for the second quarter and six-month period
ended June 30, 2007. Revenues for the three months ended June 30,
2007 were $2.3 million, up from $210,000 from the corresponding
period in 2006. The increase was due to two factors: improvements
in cost recovery from Insmed�s Expanded Access Program (EAP) to
treat patients with amyotrophic lateral sclerosis (ALS) and the
receipt of licensing income from our January 2007 agreement with
NAPO Pharmaceuticals Inc. The net loss for the second quarter of
2007 was $2.5 million, or $0.02 per share, compared with a net loss
of $8.9 million, or $0.09 per share, in the second quarter of 2006.
The year-over-year improvement was due mainly to a reduction in
selling, general and administrative (SG&A) expenses, which fell
to $1.2 million from $5.2 million in the second quarter of 2006,
and to a drop in research and development (R&D) expenses to
$3.7 million from $4.3 million. The reduction in SG&A was due
primarily to reduced litigation expenses and the elimination of
commercial expenses associated with our business restructuring
plan. The drop in R&D expenses reflected a reduction in our
clinical and commercial manufacturing activity. Interest income in
the second quarter of 2007 fell to $224,000 from $577,000 a year
earlier. This was due to a lower average cash balance on hand for
the most recent quarter. For the six months ended June 30, 2007,
revenues totaled $3.9 million, up from $263,000 in the first six
months of 2006. Consistent with second quarter results, the
increase was due to improvements in the cost recovery from our EAP
and the receipt of licensing income from our agreement with NAPO
Pharmaceuticals, together with increased sales of our lead drug
IPLEX�. The net loss for the six months ended June 30, 2007 was
$12.8 million, or $0.12 per share, compared to $22.3 million, or
$0.25 per share, for first six months of 2006. Year-over-year,
R&D expenses dropped to $9.8 million for the first half of
2007, from $11.5 million, reflecting lower litigation expenses,
which were included in R&D during the first quarter of 2006,
and reduced clinical and commercial manufacturing activity.
SG&A expenses fell to $6.5 million for the first half of 2007
from $9.0 million a year earlier, due to a combination of reduced
litigation expenses and the elimination of commercial expenses.
This reduction was partially offset by severance costs associated
with our business restructuring plan. Interest income for the first
half of 2007 was $525,000, compared to $889,000 for the first half
of 2006. Interest expense for the six months ended June 30, 2007
was $306,000, compared to $3.0 million for the first half of 2006.
The decrease in interest expense resulted from lower amortization
of the debt discount associated with our March 2005 financing, as
an acceleration of the discount took place in the first quarter of
2006 due to the conversion of notes into shares of Insmed common
stock. As of June 30, 2007, Insmed had total cash and cash
equivalents on hand of $22.3 million, compared to $24.1 million on
hand as of December 31, 2006. The $1.9 million decrease in cash and
cash equivalents reflected the use of $18.7 million for operating
activities and $500,000 utilized for the Company�s investment in
NAPO Pharmaceuticals Inc. The decrease was partially offset by net
proceeds of $17.0 million from an offering of our common stock and
warrants to purchase common stock and $300,000 from a reduced
letter of credit. Second Quarter Financing Activities On May 4,
2007, Insmed sold 20,255,367 shares of its common stock together
with warrants to purchase up to 2,025,536 shares of its common
stock. The price to the investors was $0.90 per unit, which was
comprised of one share of common stock and a warrant to purchase
0.1 share of common stock. The units were not issued or
certificated, and the shares of common stock and warrants were
immediately separable and issued separately. The warrants may be
exercised between November 3, 2007 and May 3, 2012 and have an
exercise price of $1.10 per share. The offering was made pursuant
to the Company�s effective shelf registration statement on Form S-3
previously filed with the Securities and Exchange Commission. Net
proceeds to the Company from the offering were $17.0 million.
Insmed Expected to Launch into Follow-On Biologics Market �Our
latest results clearly show not only an improving financial picture
but, perhaps more importantly, that Insmed is successfully
preparing for its launch into a substantial new market in follow-on
biologics, said Insmed President and CEO Geoffrey Allan, Ph.D. �We
believe that Congress will soon pass legislation allowing the
marketing of �biogenerics�, medicines similar to major
protein-based drugs going off-patent. If and when this legislation
passes, we believe our state-of-the-art manufacturing facility and
drug-development expertise should place us in an advantageous
position to rapidly capture a portion of this substantial
opportunity. In the meantime, our second quarter financials
indicate that Insmed has reduced its expense levels, gained a solid
revenue stream from its EAP and has decreased its burn rate,�
concluded Dr. Allan. Investor Conference Call Insmed will host a
conference call on Thursday, August 2, 2007 at 11:00 a.m. Eastern
Time to discuss the financial results for the first six months
ended June 30, 2007, and to provide a business update. Individuals
interested in listening to the live call may do so by dialing
877-407-0782 toll free within the United States and Canada, or
201-689-8567 for international callers. A telephonic replay of the
call will be available approximately two hours after the call for a
period of two weeks at 877-660-6853 from the United States and
201-612-7415, for international callers. The account # is 286 and
conference id # 249996. Individuals interested in listening to the
conference call via the Internet may do so by visiting Insmed�s
website at www.insmed.com. A replay of the call will be available
on the website for a period of 90 days. About Insmed Insmed Inc. is
a biopharmaceutical company with unique protein process development
and manufacturing experience and a proprietary protein platform
aimed at niche markets with unmet medical needs. For more
information, please visit www.insmed.com. To be added to Insmed's
investor lists, please contact Haris Tajyar at htajyar@irintl.com
or at 818-382-9702. Forward Looking Statements This release
contains forward-looking statements which are made pursuant to
provisions of Section 21E of the Securities Exchange Act of 1934.
Investors are cautioned that such statements in this release,
including statements relating to planned clinical study design,
regulatory and business strategies, plans and objectives of
management and growth opportunities for existing or proposed
products, constitute forward-looking statements which involve risks
and uncertainties that could cause actual results to differ
materially from those anticipated by the forward-looking
statements. The risks and uncertainties include, without
limitation, risks that product candidates may fail in the clinic or
may not be successfully marketed or manufactured, we may lack
financial resources to complete development of product candidates,
the FDA may interpret the results of studies differently than us,
competing products may be more successful, demand for new
pharmaceutical products may decrease, the biopharmaceutical
industry may experience negative market trends, our entrance into
the follow on biologics market may be unsuccessful, our common
stock could be delisted from the Nasdaq Global Market and other
risks and challenges detailed in our filings with the U.S.
Securities and Exchange Commission, including our Quarterly Report
on Form 10-Q for the quarter ended June 30, 2007. Readers are
cautioned not to place undue reliance on any forward-looking
statements which speak only as of the date of this release. We
undertake no obligation to publicly release the results of any
revisions to these forward-looking statements that may be made to
reflect events or circumstances that occur after the date of this
release or to reflect the occurrence of unanticipated events.
INSMED INCORPORATED Consolidated Balance Sheets (in thousands,
except share and per share data) � (unaudited) June 30, December
31, � 2007 � � 2006 � � Assets Current assets: Cash and cash
equivalents $ 22,259 $ 24,112 Restricted cash 493 407 Accounts
receivable, net - 241 Inventories - 576 Other current assets � 211
� � 87 � Total current assets 22,963 25,423 � Long-term assets:
Restricted cash - long term 2,325 2,708 Investments 437 - Deferred
financing costs, net 193 209 Property and equipment, net � 5 � � 8
� Total long-term assets � 2,960 � � 2,925 � � Total assets $
25,923 � $ 28,348 � � Liabilities and stockholders' equity Current
liabilities: Accounts payable $ 681 $ 7,187 Accrued project costs
& other 413 1,115 Payroll liabilities 1,243 1,302 Interest
payable 23 23 Deferred rent 54 54 � Convertible debt 1,139 - Debt
discount � (403 ) � - � Net convertible debt � 736 � � - � � Total
current liabilities 3,150 9,681 � Long-term liabilities:
Convertible debt 3,986 5,125 Debt discount � (1,412 ) � (1,964 )
Net long-term convertible debt 2,574 3,161 � Asset retirement
obligation � 1,921 � � � 1,626 � � Total liabilities � 7,645 � �
14,468 � � Stockholders' equity: Common stock; $.01 par value;
authorized shares 500,000,000; issued and outstanding shares,
121,708,316 in 2007 and 101,328,118 in 2006 1,217 1,013 Additional
paid-in capital 340,675 323,664 Accumulated deficit (323,551 )
(310,797 ) Accumulated other comprehensive loss: Unrealized loss on
investment � (63 ) � - � Net stockholders' equity � 18,278 � �
13,880 � � Total liabilities and stockholders' equity $ 25,923 � $
28,348 � INSMED INCORPORATED Consolidated Statements of Operations
(in thousands, except per share data - unaudited) � Three Months
Ended Six Months Ended June 30, � June 30, � 2007 � � � 2006 � � �
2007 � � � 2006 � � Sales, net $ - $ 8 $ 423 $ 8 Royalties 17 30 52
83 License income 1,045 - 1,545 - Other expanded access program
income � 1,213 � � � 172 � � � 1,915 � � � 172 � Total revenues
2,275 210 3,935 263 � Operating expenses: Cost of goods sold - 23
576 23 Research and development 3,691 4,348 9,796 11,522 Selling,
general and administrative � 1,153 � � � 5,163 � � � 6,535 � � �
8,963 � Total expenses � 4,844 � � � 9,534 � � � 16,907 � � �
20,508 � � Operating loss (2,569 ) (9,324 ) (12,972 ) (20,245 ) �
Interest income 224 577 525 889 Interest expense � (155 ) � � (164
) � � (306 ) � � (2,983 ) � Net loss $ (2,500 ) � $ (8,911 ) � $
(12,753 ) � $ (22,339 ) � Basic and diluted net loss per share $
(0.02 ) � $ (0.09 ) � $ (0.12 ) � $ (0.25 ) � Shares used in
computing basic and diluted net loss per share � 113,577 � � �
100,152 � � � 107,486 � � � 90,125 � INSMED INCORPORATED
Consolidated Statements of Cash Flows (in thousands - unaudited) �
Six Months Ended June 30, � 2007 � � 2006 � � Operating activities
Net loss $ (12,753 ) $ (22,339 ) Adjustments to reconcile net loss
to net cash used in operating activities: Depreciation and
amortization 168 2,809 Stock based compensation expense 129 481
Stock options issued for services 39 40 Changes in operating assets
and liabilities: Accounts receivable 241 (105 ) Inventory 576
(1,797 ) Other assets (124 ) (107 ) Accounts payable (6,507 ) 1,916
Accrued project costs (702 ) (636 ) Payroll liabilities (59 ) 116
Deferred rent - (165 ) Asset retirement obligation 295 296 Interest
payable � - � � (24 ) Net cash used in operating activities �
(18,697 ) � (19,515 ) � Investing activities Purchases of
investments (500 ) - Purchases of property, plant and equipment � -
� � (3,016 ) Net cash used in investing activities � (500 ) �
(3,016 ) � Financing activities Proceeds from issuance of common
stock Public offering 18,230 43,240 Issuance costs (1,266 ) (421 )
Warrants converted into shares - 8,810 Other � 83 � � 135 � Total
proceeds from issuance of common stock 17,047 51,764 Changes in
cash restricted to restricted letters of credit � 297 � � 288 � Net
cash provided by financing activities � 17,344 � � 52,052 � �
(Decrease) Increase in cash and cash equivalents (1,853 ) 29,521
Cash and cash equivalents at beginning of period � 24,112 � �
18,835 � � Cash and cash equivalents at end of period $ 22,259 � $
48,356 � � Supplemental information Cash paid for interest $ 141 $
165
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024